Matinas BioPharma Investor Presentation Deck
3
Matinas Investment Thesis: LNC Delivery Unlocks Therapeutic Value
Lipid Nanocrystals
(LNCs)
●
MAT2203
• Oral Amphotericin B - without nephrotoxicity
Phase 3-ready (Invasive Aspergillosis in 198
patients with limited or no treatment options)
• Provides effective longer-term fungicidal
stepdown therapy for Invasive Fungal Infections
●
• 12 years of exclusivity* *QIDP and Orphan designations
Intracellular delivery
Oral administration
Less toxicity
Targeting beyond the liver
Clinical Validation
of LNC Capabilities
Pipeline Products
and Opportunities
• Current efforts expanding LNC application
beyond small molecules to include delivery of
smaller oligonucleotides (ASOs, siRNA, RNAI)
• Expanding primary therapeutic applications from
infectious disease (antifungal, antibiotic,
antiviral) to inflammation and cancer
COPYRIGHT MATINAS BIOPHARMA 2024
MATINAS
BIOPHARMAView entire presentation